Request Demo

Last update 08 May 2025

Linsidomine Hydrochloride

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Linsidomine, Corvasal

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC6H11ClN4O2

InChIKeyZRFWHHCXSSACAW-UHFFFAOYSA-M

CAS Registry16142-27-1

View All Structures (2)

100 Clinical Results associated with Linsidomine Hydrochloride

100 Translational Medicine associated with Linsidomine Hydrochloride

100 Patents (Medical) associated with Linsidomine Hydrochloride

1,668

Literatures (Medical) associated with Linsidomine Hydrochloride

01 Sep 2025·Talanta

An activatable β-diketonate europium(III) complex-based probe for time-gated luminescence detection and imaging of peroxynitrite in vitro and in vivo

Article

Author: Zou, Jinhua ; Dong, Zhiyuan ; Yuan, Jingli ; Song, Bo ; Liu, Qi

Peroxynitrite (ONOO^-), one of representative reactive nitrogen species with strong oxidative and nitrative properties, is known to be associated with various human diseases, such as Alzheimer's disease, drug-induced liver injury (DILI), inflammation, and cancer. Probing its fluctuations throughout diseases holds profound promise for advancing early diagnosis and enabling prompt intervention. In this work, we designed and synthesized a β-diketonate Eu³⁺ complex-based probe, [Eu(Cy-CDHH)₃(terpy)], for the time-gated luminescence (TGL) detection of ONOO^-. The probe, composed of a cyanine-dye-conjugated β-diketonate-Eu³⁺ coordination structure, is non-luminescent due to the intramolecular energy transfer from β-diketonate to cyanine-dye, which inhibits the energy transfer from β-diketonate to central Eu³⁺ ion. Upon reaction with ONOO^-, the unsaturated CC bond of cyanine-dye is cleaved. This process leads to the recovery of the intense long-lived luminescence of the β-diketonate-Eu³⁺ complex (ϕ = 17.3 %, τ = 436 μs), showcasing characteristics of rapid response (within 10 s), high selectivity, low detection limit (17.4 nM), and low cytotoxicity. These features enable the probe to be used for the quantitative TGL detection of ONOO^- in aqueous media as well as for the background-free TGL imaging of ONOO^- in living cells under assorted stimuli. Furthermore, the probe was effectively implemented for imaging of ONOO^- in livers of drug-induced liver injury mice, revealing the up-regulation of ONOO^- levels in this disease and the therapeutic efficacy of glutathione (GSH) via precluding the onset of reactive oxygen/nitrogen species. This research paves a new way for the fabrication of lanthanide complex bioprobes, providing a useful tool for understanding the interconnection between ONOO^- and disease-related physiological processes.

14 Apr 2025·Sexual Medicine Reviews

Application of nitrates and NO-donors as a transdermal therapy for erectile dysfunction: a comprehensive review

Review

Author: Rezaiezadeh, Hojjat ; Forootanfar, Hamid ; Ranjbar Tavakoli, Marziye ; Shami, Maryam ; Langarizadeh, Mohammad Amin ; Khorasanian, Fatemeh

AbstractIntroductionErectile dysfunction (ED) is among the most prevalent urologic issues affecting men globally, with a notably high incidence rate. It significantly impacts the quality of life of patients and their sexual partners.ObjectivesGiven the increasing prevalence of ED among men in recent years, numerous pharmacotherapies have been developed to address these conditions. However, systemic drug therapies for ED are often associated with significant challenges, including drug interactions and contraindications across a wide range of medical conditions. This has prompted researchers to focus on designing drugs and dosage forms that maintain efficacy while reducing side effects, interactions, and contraindications.MethodsBuilding on previous studies, this article investigates nitrates and NO-donors with a focus on their transdermal impact, strategies for enhancing therapeutic efficiency, potential local side effects, and the evaluation of various formulations.ResultsIn this regard, organic nitrates such as nitroglycerin and isosorbide dinitrate and NO donors comprising volatile alkyl nitrites, linsidomine, sodium nitroprusside, and L-arginine are among good candidates for transdermal formulations of ED treatment. In the current article, the topical effects of these compounds, both alone and in combination with other drugs, have been thoroughly examined, including aspects such as their mechanism of action, effectiveness, side effects, and contraindications.ConclusionBased on these findings, it appears that novel formulations with enhanced absorption of these compounds could play a significant role in the treatment of ED, either as a standalone therapy or as an adjunctive treatment. Currently, most of the data are from preclinical studies and future clinical research can reveal the precise efficacy of such transdermal formulations.

01 Jan 2025·Microchemical Journal

A hepatocyte-targeting ratiometric fluorescence probe for monitoring peroxynitrite in liver injury

Author: Mao, Guo-Jiang ; Wang, Zhi-Qing ; Xu, Fen ; Li, Chun-Yan ; Long, Jia-Qin ; Li, Ting ; Li, Yongfei ; Yang, Zhi-Chao

The liver serves as the primary organ being responsible for metabolic processes and detoxification, and is particularly susceptible to suffering injury.The degree of hepatic injury can be assessed by measuring elevated peroxynitrite (ONOO-).Despite many fluorescence probes have been successfully deployed for detecting ONOO-, hepatocyte-targeting probes remain scarce.Herein, a hepatocyte-targeting ratiometric fluorescence probe, Cy-Gal, is synthesized.Cy-Gal is engineered by binding galactose with hemicyanine fluorophore, enabling targeted delivery to the liver and the emission of red fluorescence.Upon reaction with ONOO-, Cy-Gal undergoes the oxidation and cleavage of its C= C bond, resulting in the formation of O-Gal and the emission of blue fluorescence.The process demonstrates a significant emission shift of 240 nm, indicating excellent ratiometric fluorescence response to ONOO-.This enables precise ONOO- detection with remarkable sensitivity and selectivity.Moreover, Cy-Gal has hepatocyte targeting ability due to its galactose moiety, and effectively monitors exogenous and endogenous ONOO- in HepG2 cells.In particular, Cy-Gal with good hepatocyte-targeting ability can be employed for ONOO- in mice models with liver injury induced by carbon tetrachloride (CCl4) or rifampicin (RFP).

100 Deals associated with Linsidomine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Linsidomine Hydrochloride	C01DX18	DB13400

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2015	Not Applicable	Muscular Atrophy	-	L-NAME	gbnglpmxqe(foqovasvae) = pbjyycegez frcnjuaejr (exocryvzmf, 121) View more	-	10 Jun 2015
				SIN-1	gbnglpmxqe(foqovasvae) = xptvmbayov frcnjuaejr (exocryvzmf, 169) View more
7D.06 (ESH2010)	Not Applicable	NO synthases \| L-NAME \| DETA-NO ... View more	-	L-NAME	tozghwspzr(vasfcqveld) = tasvsssqnx ijhrlqootc (nixpswigha, 1.8)	Positive	01 Jun 2010
				DETA-NO	tozghwspzr(vasfcqveld) = xbalfzndro ijhrlqootc (nixpswigha, 4.5)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Linsidomine Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation